<DOC>
	<DOCNO>NCT02606903</DOCNO>
	<brief_summary>To investigate compare pharmacokinetics , safety tolerability BI 695501 administer subcutaneously via prefilled syringe autoinjector</brief_summary>
	<brief_title>Pharmacokinetics Safety BI 695501 Administered Via Prefilled Syringe Autoinjector</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male , nonathletic* Caucasian subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( blood pressure [ BP ] , pulse rate [ PR ] ) , 12lead ECG , clinical laboratory test . Age 18 65 year ( inclusive ) BMI 18 30 kg/m2 ( inclusive ) BMI 18 &lt; 20 , BMI 20 &lt; 25 , BMI 25 &lt; =30 Signed date write informed consent prior admission trial accordance Good Clinical Practice ( GCP ) local legislation . Subjects agree use acceptable method contraception trial 6 month dose trial drug . Nonathletic define person perform one hour exercise per week Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator . Any evidence concomitant disease judge clinically relevant investigator include gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder . History relevant orthostatic hypotension , faint spell , blackout . Chronic relevant acute infection . Positive result HIV , HBV , hepatitis C ( Hep C ) screen . History relevant allergy hypersensitivity include allergy trial medication , excipients device material ( e.g . natural rubber latex ) . Intake drug long halflife ( 24 hour ) within 30 day less 5 halflives respective drug prior administration trial medication . Within 10 day prior administration trial medication , use drug might reasonably influence result trial . Previous exposure biologic drug . Intake investigational drug another trial within 2 month prior intake trial medication trial intake investigational drug course trial . Smoker ( 10 cigarette 3 cigar 3 pipe per day ) . Inability refrain smoke day confinement trial site . Alcohol abuse ( consumption 4 units/day ) . Unwillingness/inability refrain intake alcoholic beverage 48 hour prior trial medication administration Day 14 post trial medication administration ; and/or limit alcohol intake maximum 3 unit per day e.o.t . Drug abuse positive drug screening . Blood donation 100 mL within 30 day prior administration trial medication intend donation trial . Intention perform excessive physical activity within 1 week prior administration trial medication contact sport entire trial unwilling avoid vigorous exercise 14 day post dose . Inability comply dietary regimen trial site . Any outofrange laboratory value consider clinically significant investigator ; subject creatine kinase ( CK ) value 2 time upper limit normal ( ULN ) Day 1 exclude participation . Subject assess unsuitable inclusion investigator , instance , consider able understand comply trial requirement , condition would allow safe participation trial . Subjects immunological disorder autoimmune disorder , ( e.g. , RA , lupus erythematosus , scleroderma , etc. ) . Subject receive live vaccine within 12 week prior enrol trial . History TB positive finding IGRA . Evidence skin irritation infection plan injection place .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>